Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Brain Ischemia - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Brain Ischemia - Pipeline Review, H2 2015', provides an overview of the Brain Ischemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Brain Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Ischemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Brain Ischemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Ischemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Brain Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Brain Ischemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Brain Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Brain Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Brain Ischemia Overview 7 Therapeutics Development 8 Pipeline Products for Brain Ischemia - Overview 8 Pipeline Products for Brain Ischemia - Comparative Analysis 9 Brain Ischemia - Therapeutics under Development by Companies 10 Brain Ischemia - Therapeutics under Investigation by Universities/Institutes 11 Brain Ischemia - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Brain Ischemia - Products under Development by Companies 14 Brain Ischemia - Products under Investigation by Universities/Institutes 15 Brain Ischemia - Companies Involved in Therapeutics Development 16 CohBar Inc. 16 Immune Pharmaceuticals Inc. 17 Lixte Biotechnology Holdings, Inc. 18 NeuroNascent, Inc. 19 NeurOp, Inc 20 Prolong Pharmaceuticals 21 Spectrum Pharmaceuticals, Inc. 22 Sylentis S.A. 23 The International Biotechnology Center (IBC) Generium 24 Vect-Horus S.A.S 25 Brain Ischemia - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 AB-002 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 F-573 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 GNR-014 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Humanin - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 LAU-0901 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 LB-100 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 LB-102 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 NP-10679 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 phycocyanobilin - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Sanguinate - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Small Molecules for Brain Ischemia - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Small Molecules to Antagonize Gpr17 for Brain Ischemia - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 SPI-1620 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Stem Cell Therapy for Ischemia - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Synthetic Peptide for Central Nervous System Disorders - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 VHN-439 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Brain Ischemia - Recent Pipeline Updates 60 Brain Ischemia - Dormant Projects 63 Brain Ischemia - Discontinued Products 64 Appendix 65 Methodology 65 Coverage 65 Secondary Research 65 Primary Research 65 Expert Panel Validation 65 Contact Us 65 Disclaimer 66
List of Tables
Number of Products under Development for Brain Ischemia, H2 2015 8 Number of Products under Development for Brain Ischemia - Comparative Analysis, H2 2015 9 Number of Products under Development by Companies, H2 2015 10 Number of Products under Investigation by Universities/Institutes, H2 2015 11 Comparative Analysis by Clinical Stage Development, H2 2015 12 Comparative Analysis by Early Stage Development, H2 2015 13 Products under Development by Companies, H2 2015 14 Products under Investigation by Universities/Institutes, H2 2015 15 Brain Ischemia - Pipeline by CohBar Inc., H2 2015 16 Brain Ischemia - Pipeline by Immune Pharmaceuticals Inc., H2 2015 17 Brain Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015 18 Brain Ischemia - Pipeline by NeuroNascent, Inc., H2 2015 19 Brain Ischemia - Pipeline by NeurOp, Inc, H2 2015 20 Brain Ischemia - Pipeline by Prolong Pharmaceuticals, H2 2015 21 Brain Ischemia - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 22 Brain Ischemia - Pipeline by Sylentis S.A., H2 2015 23 Brain Ischemia - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015 24 Brain Ischemia - Pipeline by Vect-Horus S.A.S , H2 2015 25 Assessment by Monotherapy Products, H2 2015 26 Number of Products by Stage and Target, H2 2015 28 Number of Products by Stage and Mechanism of Action, H2 2015 30 Number of Products by Stage and Route of Administration, H2 2015 32 Number of Products by Stage and Molecule Type, H2 2015 34 Brain Ischemia Therapeutics - Recent Pipeline Updates, H2 2015 60 Brain Ischemia - Dormant Projects, H2 2015 63 Brain Ischemia - Discontinued Products, H2 2015 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
